Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2 Study of OBI-999 in Patients with Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, 18 years of age or older at the time of consent.~2. Provide written informed consent prior to performing any study related procedure.~3. Histologically or cytologically confirmed patients with advanced solid tumors.~4. Patients must have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy. In the latter case, the informed consent must state the effective therapies the patient is declining.~5. Measurable disease (i.e., at least one measurable lesion per RECIST 1.1)~6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~7. Adequate organ function defined as:~   a. Hepatic:~   i. Serum ALT ≤3 × upper limit of normal (ULN), ≤5 × ULN in the presence of liver metastases~   ii. Serum AST ≤3 × ULN, ≤5 × ULN in presence of liver metastases~   iii.Serum bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome or hemolysis)~   b. Renal:~   i. Creatinine clearance \>50 mL/minute using Cockcroft Gault equation~   c. Hematologic:~   i. Absolute neutrophil count ≥1,500/µL~   ii. Platelets ≥100,000/µL~   iii. Hemoglobin ≥8 g/dL~8. Patient is willing and able to comply with all protocol required assessments, visits, and procedures, including a pretreatment tumor biopsy. Archival tumor biopsies are acceptable at baseline.~9. Females of childbearing potential must have negative serum pregnancy test prior to starting study therapy, and agree to use a reliable form of contraceptive during the study treatment period and for at least 120 days following the last dose of study drug.~   Patient not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in study. Postmenopausal is defined as 12 months with no menses without an alternative medical cause.~   Male patients must agree to use an adequate method of contraception during the study treatment period and for at least 120 days following the last dose of study drug.~10. Cannot be breast feeding.~11. Patients with human immunodeficiency virus (HIV) infection are eligible if CD4+ T cell counts ≥ 350 cells/uL; patients on antiretroviral therapy (ART) should be on an established dose for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrollment.~12. Patients with serological evidence of chronic hepatitis B virus (HBV) infection are eligible if they have an HBV viral load below the limit of quantification with or without concurrent viral suppressive therapy.~13. Patients with a history of hepatitis C virus (HCV) infection should have completed curative antiviral treatment and have a viral load below the limit of quantification.~14. Patients in Part B (Cohort-Expansion) must have documented Globo H H score of at least 100 from a qualified laboratory IHC assay in one of the sponsor-selected tumor types to be enrolled in the respective cohort:~    * Cohort 1: Pancreatic cancer~   * Cohort 2: Esophageal cancer~   * Cohort 3: Gastric cancer~   * Cohort 4: Colorectal cancer~   * Cohort 5: Basket (any solid tumor type other than those included in Cohorts 1 through 4).~Exclusion Criteria:~1. Less than 3 weeks from prior cytotoxic chemotherapy or radiation therapy; and less than 5 half-lives or 3 weeks, whichever is shorter, from prior biologic therapies, prior to the first dose of OBI 999.~2. Has undergone a major surgical procedure (as defined by the Investigator) or significant traumatic injury within 28 days prior to the first dose of OBI 999.~3. Sensory or motor neuropathy of Grade 2 or greater.~4. Patients with a history of solid organ transplant.~5. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using NCI CTCAE version 5.0), except for alopecia and laboratory values listed in the inclusion criteria.~6. Receipt of any prior therapy targeting Globo H.~7. Known hypersensitivity to OBI 999 or its excipients.~8. Has known untreated central nervous system metastases. Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\]) during the screening period.~9. Has significant clinical cardiac abnormality (e.g., clinical heart failure or unstable angina)~10. Any medical co morbidity that is life threatening or, in the opinion of the Investigator, renders the patient unsuitable for participation in a clinical trial due to possible noncompliance, would place the patient at an unacceptable risk and/or potential to affect interpretation of results of the study.~11. Is receiving any concurrent prohibited medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OBI-999 Escalation phase (Type: EXPERIMENTAL): Part A: Five cohorts at escalating dose levels 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg (capping calculations at a maximum at 100 kg) of OBI-999 liquid form via IV infusion to establish maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D).
- OBI-999 Expansion Phase (Type: EXPERIMENTAL): Part B: Five cohorts of patients at RP2D of OBI-999 liquid form, as determined from Part A, via IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy